{"classes":[{"categories":[{"measurements":[{"comment":"Here, NA signifies that median and upper limit of confidence interval (CI) was not estimable due to less number of events.","groupId":"OG000","lowerLimit":"703","upperLimit":"NA","value":"NA"},{"groupId":"OG001","lowerLimit":"490","upperLimit":"1232","value":"715.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"43"},{"groupId":"OG001","value":"42"}],"units":"Participants"}],"description":"PFS is defined as the time between randomization and initial documented PD according to the CRAB - International Myeloma Working Group (IMWG) criteria or date of death, whichever occurs first. PD is defined as presence of an M-component in serum plus clonal plasma cells in the bone marrow plus 1 or more of the following: Calcium elevation (\\> 11.5 mg/dL \\[\\> 2.88 mmol/L\\]); Renal insufficiency (creatinine \\> 2 mg/dL \\[177 \\[micro mol/L or more\\]); Anemia (\\<10 g/dL or 2 g/dL) lower than LLN) \\[hemoglobin \\< 6.5 mmol/L or 1.25 mmol/L lower than LLN\\]); Bone disease (lytic lesions or osteopenia).","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received 15 milligram per kilogram (mg/kg) of siltuximab as a 1-hour intravenous (IV) infusion every 4 weeks until disease progression, unacceptable toxicity, withdrawal of consent, or the end of the study (up to 4 years after randomization of the last participant).","id":"OG000","title":"Siltuximab"},{"description":"Participants received placebo as a 1-hour IV infusion every 4 weeks until disease progression, unacceptable toxicity, withdrawal of consent, or the end of the study (up to 4 years after randomization of the last participant).","id":"OG001","title":"Placebo"}],"paramType":"MEDIAN","populationDescription":"ITT population included participants who were randomly assigned to siltuximab or placebo treatment group based on an IVRS.","reportingStatus":"POSTED","timeFrame":"Up to 4.7 Years","title":"Progression-Free Survival","type":"SECONDARY","unitOfMeasure":"Days"}